These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 16289766)

  • 21. A vaccine against S. pyogenes: design and experimental immune response.
    Guilherme L; Postol E; Freschi de Barros S; Higa F; Alencar R; Lastre M; Zayas C; Puschel CR; Silva WR; Sa-Rocha LC; Sa-Rocha VM; Pérez O; Kalil J
    Methods; 2009 Dec; 49(4):316-21. PubMed ID: 19409999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid core peptide technology and group A streptococcal vaccine delivery.
    Olive C; Batzloff MR; Toth I
    Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
    Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
    J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced immunogenicity of an anti-caries vaccine encoding a cell-surface protein antigen of Streptococcus mutans by intranasal DNA prime-protein boost immunization.
    Li Y; Jin J; Yang Y; Bian Z; Chen Z; Fan M
    J Gene Med; 2009 Nov; 11(11):1039-47. PubMed ID: 19718694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization with SsEno fails to protect mice against challenge with Streptococcus suis serotype 2.
    Esgleas M; Dominguez-Punaro Mde L; Li Y; Harel J; Dubreuil JD; Gottschalk M
    FEMS Microbiol Lett; 2009 May; 294(1):82-8. PubMed ID: 19493012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal immunization with a live Streptococcus suis isogenic ofs mutant elicited suilysin-neutralization titers but failed to induce opsonizing antibodies and protection.
    Kock C; Beineke A; Seitz M; Ganter M; Waldmann KH; Valentin-Weigand P; Baums CG
    Vet Immunol Immunopathol; 2009 Dec; 132(2-4):135-45. PubMed ID: 19505730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
    Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
    Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
    Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.
    Wozniak A; García P; Geoffroy EA; Aguirre DB; González SA; Sarno VA; Dale JB; Salazar-Echegarai FJ; Vera A; Bueno SM; Kalergis AM
    Clin Vaccine Immunol; 2014 Sep; 21(9):1343-9. PubMed ID: 25056362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective immunity evoked by locally administered group A streptococcal vaccines in mice.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    J Immunol; 1988 Oct; 141(8):2767-70. PubMed ID: 3049817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
    Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
    mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.
    Park HS; Cleary PP
    Infect Immun; 2005 Dec; 73(12):7878-86. PubMed ID: 16299278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
    García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
    Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moving forward: a mucosal vaccine against group A streptococcus.
    Georgousakis MM; McMillan DJ; Batzloff MR; Sriprakash KS
    Expert Rev Vaccines; 2009 Jun; 8(6):747-60. PubMed ID: 19485755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
    Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
    Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.
    Vohra H; Dey N; Gupta S; Sharma AK; Kumar R; McMillan D; Good MF
    Res Microbiol; 2005 May; 156(4):575-82. PubMed ID: 15862457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
    Mansour NM; Abdelaziz SA
    Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci.
    Courtney HS; Hasty DL; Dale JB
    Infect Immun; 2003 Sep; 71(9):5097-103. PubMed ID: 12933852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.